Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.

Mycobacterium tuberculosis preclinical models rifamycins site-of-disease pharmacokinetics tuberculous meningitis

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
19 Jul 2024
Historique:
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 19 7 2024
Statut: aheadofprint

Résumé

Tuberculous meningitis (TBM) has a high mortality, possibly due to suboptimal therapy. Drug exposure data of antituberculosis agents in the central nervous system (CNS) are required to develop more effective regimens. Rifabutin is a rifamycin equivalently potent to rifampin in human pulmonary tuberculosis. Here, we show that human-equivalent doses of rifabutin achieved potentially therapeutic exposure in relevant CNS tissues in a rabbit model of TBM, supporting further evaluation in clinical trials.

Identifiants

pubmed: 39028192
doi: 10.1128/aac.00783-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0078324

Auteurs

Sean Wasserman (S)

Institute for Infection and Immunity, St. George's, University of London, London, United Kingdom.
Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Rosleine Antilus-Sainte (R)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Noha Abdelgawad (N)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Narineh M Odjourian (NM)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Melissa Cristaldo (M)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Maureen Dougher (M)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Firat Kaya (F)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Matthew Zimmerman (M)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Paolo Denti (P)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Martin Gengenbacher (M)

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.

Classifications MeSH